{"id":"NCT04142242","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49","officialTitle":"Safety and Immunogenicity of a Single Dose of MenACYW Conjugate Vaccine at Least 3 Years Following Initial Vaccination With Either MenomuneÂ® Vaccine or MenACYW Conjugate Vaccine in Older Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-10-04","primaryCompletion":"2020-04-01","completion":"2022-05-25","firstPosted":"2019-10-29","resultsPosted":"2021-04-26","lastUpdate":"2025-09-11"},"enrollment":471,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Infection (Healthy Volunteers)"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine","otherNames":["MenACYW Conjugate vaccine","MenQuadfi"]},{"type":"OTHER","name":"Blood sample","otherNames":[]}],"arms":[{"label":"Group 1: MenACYW Conjugate Vaccine (MET 49 - Menomune-primed Participants)","type":"EXPERIMENTAL"},{"label":"Group 2: MenACYW Conjugate Vaccine (MET49 - MenACYW Conjugate Vaccine-primed Participants)","type":"EXPERIMENTAL"},{"label":"Group 3: MenACYW Conjugate Vaccine (MET49: Menomune-primed Participants)","type":"EXPERIMENTAL"},{"label":"Group 4: MenACYW Conjugate Vaccine (MET49: MenACYW-primed Participants)","type":"EXPERIMENTAL"},{"label":"Group 5: Menomune-primed Participants (MET44)","type":"OTHER"},{"label":"Group 6: MenACYW Conjugate Vaccine-primed Participants (MET44)","type":"OTHER"}],"summary":"Primary Objective:\n\nTo demonstrate sufficiency of the vaccine seroresponse to meningococcal serogroups A, C, W, and Y following administration of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W 135) Tetanus Toxoid (MenACYW) Conjugate vaccine to Group 1 participants (who received primary vaccination with Menomune vaccine greater than or equal to \\[\\>= 3\\] years earlier at \\>= 56 years of age in Study MET49).\n\nSecondary Objectives:\n\nSecondary Objective 1 - To demonstrate sufficiency of the vaccine seroresponse to meningococcal serogroups A, C, W, and Y following administration of a single dose of MenACYW Conjugate vaccine to Group 2 participants (who received primary vaccination with MenACYW Conjugate vaccine \\>= 3 years earlier at \\>= 56 years of age in Study MET49).\n\nSecondary Objective 2 - To describe vaccine seroresponse rates with respect to serogroups A, C, W, and Y in serum specimens collected 6 days (window, 5-7) post-vaccination in approximately 60 participants from Group 1 (Menomune-primed) and approximately 60 participants from Group 2 (MenACYW Conjugate vaccine-primed).\n\nSecondary Objective 3 - To describe antibody persistence \\>= 3 years after primary vaccination with Menomune vaccine or MenACYW Conjugate vaccine for participants from all groups.","primaryOutcome":{"measure":"Stage I: Percentage of Participants With Seroresponse for Meningococcal Serogroups A, C, W & Y Measured by Serum Bactericidal Assay Using Human Complement (hSBA) After Vaccination With MenACYW Conjugate Vaccine in Study MEQ00066: Group 1 (Menomune-primed)","timeFrame":"Day 30 (post-vaccination) in study MEQ00066","effectByArm":[{"arm":"Group 1: MenACYW Conjugate Vaccine (MET 49 - Menomune-primed Participants)","deltaMin":60.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"59 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":34,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["39555800","36632042"],"seeAlso":["https://www.trialsummaries.com/Study/StudyDetails?id=25310&tenant=MT_SNY_9011"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":151},"commonTop":["Myalgia","Injection Site Pain","Headache","Malaise","Injection Site Erythema"]}}